bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Data from In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice
Authors: Song Yinhong , Liu Yalan , Hu Rong , Su Min , Rood Debra , Lai Laijun
Published: April 2023

Supplemental Table 1. Primers used for cloning of human IL-7/IL-15, and IL-15 genes into expression vectors; Supplemental Figure 1. rIL-7/IL-15 has a lower in vitro lymphocyte-stimulating activity than equimolar amounts of rIL-7 and rIL-15; Supplemental Figure 2. rIL-7/IL-15 does not inhibit the growth of B16F10 melanoma or CT-26 colon cancer in vitro; Supplemental Figure 3. rIL-7/IL-15 treatment increases the numbers of CD4+ and CD8+ T cells, NK and NKT cells and DCs, but decreases the number of Tregs in the spleen of cancer-bearing mice; Supplemental Figure 4. rIL-7/15 inhibits the formation of pulmonary metastases by colon cancer cells.
Supplementary Figures S1-S6 and Tables S1-S6 from Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms
Authors: Pinkerneil Maria , Hoffmann Michèle J. , Deenen René , Köhrer Karl , Arent Tanja , Schulz Wolfgang A. , Niegisch Günter
Published: April 2023

Supplementary Figure S1. Expression of HDAC1/HDAC2 in urothelial cancer cell lines. Supplementary Figure S2. Effects of HDAC1/2 specific inhibition via Romidepsin and Givinostat on morphology of UCCs and control cells. Supplementary Figure S3. Relation of DNA damage - associated Î³H2A.X and 53-BP1 foci in the UCCs VM-CUB1 and UM-UC-3 to specific HDAC1 and HDAC2 inhibition Supplementary Figure S4. Quantification of mitosis and aberrant nuclei after specific HDAC1/2 inhibition via Romidepsin and Givinostat in VM-CUB1 and UM-UC-3 cells. Supplementary Figure S5. Results of RNA expression profiling after pharmacological HDAC1/2 inhibition via Romidepsin and Givinostat and siRNA mediated knockdown of HDAC1/2 in VMCUB1 and UM-UC-3 cells. Supplementary Figure S6. Investigation of cell death mechanisms after specific siRNA mediated and pharmacological HDAC1/2 inhibition in UCCs. Supplementary Tab S1. Bladder cancer cell lines used in this study and their origins. Supplementary Tab S2. Primer assays for RT-PCR. Supplementary Tab S3. Antibodies used for western blot analyses. Supplementary Tab S4. IC50 values of HDAC1/2 inhibitors in UCCs and control cells. Supplementary Tab S5. Deregulated gene expression in VM-CUB1 and UM-UC-3 cells following HDAC inhibitor treatment. Supplementary Tab S6. Commonly differentially expressed genes in Romidepsin/Givinostat/siRNA HDAC1/2 treated VM-CUB and UM-UC-3 cells.
Supplemental Figure 1 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Schematic of the survival study including a cartoon demonstrating the methodology for tumor generation
Supplementary Material and Supplementary Table 1 from Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104
Authors: Yates James W.T. , Ashton Susan , Cross Darren , Mellor Martine J. , Powell Steve J. , Ballard Peter
Published: April 2023

Full model description and Supplementary Table 1: Parameter estimates
Supplementary Methods and Supplementary Figure Legends from The Role of HMGB1 in Radioresistance of Bladder Cancer
Authors: Shrivastava Sanhita , Mansure Jose Joao , Almajed Wael , Cury Fabio , Ferbeyre Gerardo , Popovic Marija , Seuntjens Jan , Kassouf Wassim
Published: April 2023

Legends and additional methods for supplementary figures.
Figure S4 from The Role of HMGB1 in Radioresistance of Bladder Cancer
Authors: Shrivastava Sanhita , Mansure Jose Joao , Almajed Wael , Cury Fabio , Ferbeyre Gerardo , Popovic Marija , Seuntjens Jan , Kassouf Wassim
Published: April 2023

UM-UC5: Autophagy inhibition upon HMGB1 knockdown
Supplementary figure 4 from HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Authors: Court Karem A. , Hatakeyama Hiroto , Wu Sherry Y. , Lingegowda Mangala S. , Rodríguez-Aguayo Cristian , López-Berestein Gabriel , Ju-Seog Lee , Rinaldi Carlos , Juan Eduardo J. , Sood Anil K. , Torres-Lugo Madeline
Published: April 2023

(A) Representative temperature profile of one mouse with HeyA8 subcutaneous tumor models exposed to MFH. (B) Final relative tumor volume of HeyA8 subcutaneous tumor model (C) HeyA8 positive staining for cleaved caspase-3 in MFH treated tumors siControl (left), siControl+MFH (right), from tumors collected at day 19. The primary antibody was cleaved caspase-3 (Biocare Medical, 1:1000) was incubated overnight and incubated with HPR-conjugated secondary antibody, visualized with 3,3'-diaminobenzidine chromogen and counterstained with Gill's hematoxylin.
Figure S3 from The Role of HMGB1 in Radioresistance of Bladder Cancer
Authors: Shrivastava Sanhita , Mansure Jose Joao , Almajed Wael , Cury Fabio , Ferbeyre Gerardo , Popovic Marija , Seuntjens Jan , Kassouf Wassim
Published: April 2023

UM-UC5 Comet Assay Results
Supplementary figure 3 from HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Authors: Court Karem A. , Hatakeyama Hiroto , Wu Sherry Y. , Lingegowda Mangala S. , Rodríguez-Aguayo Cristian , López-Berestein Gabriel , Ju-Seog Lee , Rinaldi Carlos , Juan Eduardo J. , Sood Anil K. , Torres-Lugo Madeline
Published: April 2023

(A) Lysosome permeability when cells were exposed to PES for 24 hours in 35mm dish plates. Permeability was determined by flow cytometry using acridine orange. Flow cytometry measurements were performed with an Accuri C6 flow cytometer (BD Biosciences) and a 488nm argon laser. 15,000 events were measured. A positive control consisted of cells treated with hydrogen peroxide (Sigma-Aldrich) 0.3 ÂµM for 30 min. (B) Cathepsin B release when SKOV3 cells were exposed to PES for 24 hours. Nucleus was stained with Hoescht (blue) and Cathepsin B was stained with with Magic Red (red). cells were dyed with Magic Red{trade mark, serif} Cathepsin B Assay Kit in in glass bottom dishes (Mattek). (C) Representative histograms showing percent of pale cells as a result of exposure to PES at 10, 20 and 30 uM for 24 hours. (D) Cell viability of HeyA8 cells when exposed to MFH at 43ËšC at various times and PES concentrations. (E) Cell viability when ovarian cancer cell lines were exposed to MFH at 41ËšC (left) and 43ËšC (Right) over time.
Figure S2 from The Role of HMGB1 in Radioresistance of Bladder Cancer
Authors: Shrivastava Sanhita , Mansure Jose Joao , Almajed Wael , Cury Fabio , Ferbeyre Gerardo , Popovic Marija , Seuntjens Jan , Kassouf Wassim
Published: April 2023

UM-UC5: Phosphorylation of H2Ax post radiation
Supplementary figure 1 from HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Authors: Court Karem A. , Hatakeyama Hiroto , Wu Sherry Y. , Lingegowda Mangala S. , Rodríguez-Aguayo Cristian , López-Berestein Gabriel , Ju-Seog Lee , Rinaldi Carlos , Juan Eduardo J. , Sood Anil K. , Torres-Lugo Madeline
Published: April 2023

Particle characterization. (A) Specific Absorption Rate (SAR) values as a function of magnetic field intensity. Particles were heated from 25 to 800 ÂºC in air using a TA Instruments 2950. Specific absorption rate (SAR) was determined from the heat balance equation using a particle concentration of approximately 1.6mg core/ml suspended in water. The magnetic field was increased and applied for 200s in an Easy Heat ( Ambrell). The temperature was measured with a Luxtron Fluorometric Thermoprobe (LumaSense Technology). (B) Particle size distribution as determiend by dynamic light scattering. Particle hydrodynamic diameter was measured with particles suspended in deionized water at a concentration of 0.01 mg/ml in a Brookhaven Instruments BI-90 Plus Particle Size Analyzer (Holtsville, NY, USA). A thermo-gravimetric analysis was performed to determine the amount of CMDx attached to the magnetic core of the nanoparticles.
Supplementary Material from HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Authors: Court Karem A. , Hatakeyama Hiroto , Wu Sherry Y. , Lingegowda Mangala S. , Rodríguez-Aguayo Cristian , López-Berestein Gabriel , Ju-Seog Lee , Rinaldi Carlos , Juan Eduardo J. , Sood Anil K. , Torres-Lugo Madeline
Published: April 2023

Supplementary protocol, figure legends and tables. Supplementary Table S1. Cumulative Equivalent Minutes; Supplementary Table S.2 The top 20 genes upregulated by MFH at 43ËšC and 30 min; Supplementary Table S.3 The top 10 genes downregulated by MFH at 43ËšC and 30 min; Supplementary Tables S.4 IC50 values of PES in ovarian cancer cell lines; Supplementary Table S.5 Combination index parameters from CompSyn; Supplementary Table S.6 Combination index values for HeyA8 cells treated in combination with various concentrations of PES and various exposure times of MFH at 43ËšC; Supplementary Table S.7 HSPA6 RNA interference and MFH decreased subcutaneous HeyA8 P values from relative tumor volume. The P values were calculated using the nonparametric test Mann-Whithey.
Supplementary table 1 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Array gene list by knock down of POSTN
Supplementary figure legends from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Supplementary figure legends
Supplementary Tables S1-S2; Supplementary Figures S1-S4; and Supplementary Materials and Methods from RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break–Inducing Anticancer Drugs
Authors: Chang Hong-Yi , Chang Ting-Chia , Huang Wen-Ya , Lee Chung-Ta , Yen Chia-Jui , Tsai Yuh-Shyan , Tzai Tzong-Shin , Chen Shu-Hui , Chow Nan-Haw
Published: April 2023

Supplementary Materials Including two supplementary Tables, four supplementary figures, supplementary materials and methods. Supplementary Table S1. Proteins associated with nuclear RON identified by co-IP -LC-MS/MS. Supplementary Table S2. The emPAI value corresponds to relative abundance of the MS/MS identification. Supplementary Fig S1. Nuclear translocation of RON in response to anti-cancer drugs. Supplementary Fig S2. Co-localization of nuclear RON with Ku70/DNA-PKcs complex in presence of doxorubicin, epirubicin or mitomucon C. Supplementary Fig S3. Expression of phospho-ATM and phospho-DNA-PKcs in TSGH8301 cells under hypoxia. Supplementary Fig S4. Significance of RON on survival of TSGH8301 stable cells under hypoxia in the presence of etoposide or cisplatin. Supplementary materials and methods for trypsin digestion and LC-MS/MS identification.
Supplementary figure S6 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Gene expression changes were quantified in relation to POSTN expression.
Supplementary Figures 1-7 from Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial–Stromal Tumors by Targeting PDGFR-β
Authors: Jachetti Elena , Rigoni Alice , Bongiovanni Lucia , Arioli Ivano , Botti Laura , Parenza Mariella , Cancila Valeria , Chiodoni Claudia , Festinese Fabrizio , Bellone Matteo , Tardanico Regina , Tripodo Claudio , Colombo Mario P.
Published: April 2023

Supplementary Figure 1. Histologic evaluation of adenocarcinoma and NE tumors from TRAMP mice; Supplementary Figure 2. MCs infiltration in prostates of TRAMP mice; Supplementary Figure 3. OPT 7714 cells originate NE tumors in vivo; Supplementary Figure 4. Murine B16 F10 cells express cKit and PDGFR-β; Supplementary Figure 5. Human PC3 cells express cKit but are insensitive to Imatinib treatment; Supplementary Figure 6. Murine normal seminal vesicles do not express PDGFR-β; Supplementary Figure 7. Human phyllodes breast tumors express PDGFR-β.
Supplementary Protein Sequences from A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells
Authors: Schmittnaegel Martina , Hoffmann Eike , Imhof-Jung Sabine , Fischer Cornelia , Drabner Georg , Georges Guy , Klein Christian , Knoetgen Hendrik
Published: April 2023

Protein sequences of all recombinant fusion proteins described in the manuscript
Supplementary figure S2 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Treatment with bevacizumab increases the expression of TGF beta1 via POSTN in GSC11 tumors.
Supplementary Figure 2 from High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer
Authors: Schouten Philip C. , Vollebergh Marieke A. , Opdam Mark , Jonkers Martijn , Loden Martin , Wesseling Jelle , Hauptmann Michael , Linn Sabine C.
Published: April 2023

Analysis of genomic loss of the XIST locus by array comparative genomic hybridization
Supplementary figure S1 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Knockdown of POSTN expression decreases GSC11 tumor volume and invasion.
Supplemental Tables from High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer
Authors: Schouten Philip C. , Vollebergh Marieke A. , Opdam Mark , Jonkers Martijn , Loden Martin , Wesseling Jelle , Hauptmann Michael , Linn Sabine C.
Published: April 2023

Supplemental Table 1 - Description of the study according to REMARK criteria. Supplemental Table 2 - Survival analysis of XIST and 53BP1 in non-BRCA1-like patients. Supplemental Table 3 - Clinical characteristics of the full trial population for which 53BP1 status was available. Supplemental Table 4 - Cox Proportional Hazards Model for Recurrence Free Survival including prognostic effect of 53BP1 and chemotherapy effect by 53BP1 in the full trial population for which 53BP1 status was available. Supplemental Table 5 - Clinical characteristics of the triple negative trial population for which 53BP1 status was available. Supplemental Table 6 - Cox Proportional Hazards Model for Recurrence Free Survival including prognostic effect of 53BP1 and chemotherapy effect by 53BP1 in triple negative trial population for which 53BP1 status was available. Supplemental Table 7 - Cox Proportional Hazards Model for Recurrence Free Survival including prognostic effect of 53BP1 and chemotherapy effect by 53BP1 in the full trial population for which 53BP1 status was available. Supplemental Table 8 - Cox Proportional Hazards Model for Recurrence Free Survival including prognostic effect of 53BP1 and chemotherapy effect by 53BP1 in triple negative trial population
Table S3 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

Distribution of clonal abnormalities in cell line 4T1
Supplemental Figure 1 from High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer
Authors: Schouten Philip C. , Vollebergh Marieke A. , Opdam Mark , Jonkers Martijn , Loden Martin , Wesseling Jelle , Hauptmann Michael , Linn Sabine C.
Published: April 2023

Kaplan-Meier curves of the non-BRCA1-like cohort split by XIST-53BP1 and chemotherapy regimen.
Figure S3 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

In vitro flow cytometric analysis of the effects of folic acid on cellular uptake of the synthesized polymers. Flow cytometry demonstrated equivalent forward shifts in A, 4T1 cells stained with P-Alexa647 and B, 4T1 cells stained with P-Alexa647-FA. Equivalent forward shifts are also seen in C, BMMs stained with Alexa647 and D, BMMs stained with P-Alexa647-FA.
Figure S2 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

Representative karyotype from A, 4T1 (MSKCC) and B, 4T1 (ATCC).
Figure S1 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

A summary of P-Alexa647-FA synthesis is shown, with the final molecular struture.
Supplementary Figure 1 from FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model
Authors: Gstalder Cécile , Ader Isabelle , Cuvillier Olivier
Published: April 2023

Effect of FTY720 and/or gemcitabine treatment on complete blood count.
Supplemental Figure S3 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Carboplatin and combination treatment induces accumulation in S and G2/M phases in TMD231 cells.
Supplemental Figure S2 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Total apoptosis/necrosis in normal fibroblast cells.
Supplemental Figure S1 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Combination Nutlin-3a/carboplatin treatment decreases combination index (CI) values in a panel of breast cancer cell lines.
Supplementary Figure S2 from MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma
Authors: Filocamo Gessica , Brunetti Mirko , Colaceci Fabrizio , Sasso Romina , Tanori Mirella , Pasquali Emanuela , Alfonsi Romina , Mancuso Mariateresa , Saran Anna , Lahm Armin , Di Marcotullio Lucia , Steinkühler Christian , Pazzaglia Simonetta
Published: April 2023

Nucleotide sequence of the Smo gene around the triplet coding for the D477 position
Supplementary Figure Legends from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 4 from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

Immune cell infiltrations upon cerulein and GSK-3i treatment
Table S3 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Summary of Median Survival Statistics from C4-2B Xenograft Study
Supplementary Figure 2 from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

Expression luciferase activity upon genetic an pharmacolgical modification of NFATc2 and GSK-3Î²
Table S1 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Phenotype of T-cells used in Xenograft Studies
Supplementary Figure 1 from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

In vivo and in vitro functional studies upon genetic and pharmacological GSK-3Î² inhibition
Supplementary Methods from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Supplementary Methods and Supplementary Figure Legends
Figure S3 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Serum levels of human PSA from day 56 of the MDA-PCa-2b xenograft study (as shown in Figures 5C, 5D).
Supplementary data from Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics
Authors: Arpin Carolyn C. , Mac Stephen , Jiang Yanlin , Cheng Huiwen , Grimard Michelle , Page Brent D.G. , Kamocka Malgorzata M. , Haftchenary Sina , Su Han , Ball Daniel P. , Rosa David A. , Lai Ping-Shan , Gómez-Biagi Rodolfo F. , Ali Ahmed M. , Rana Rahul , Hanenberg Helmut , Kerman Kagan , McElyea Kyle C. , Sandusky George E. , Gunning Patrick T. , Fishel Melissa L.
Published: April 2023

This file contains a detailed description of the synthesis as well as the characterization of lead compounds PG-S3-001, PG-S3-002, and PG-S3-003. Results pertaining to the interaction of PG-S3-001 with relevant kinases is also included; Table 1. Results of Kinome Screen for Kinases involved in Regulation of STAT3.
Figure S2 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

A. Relative cytokine release observed after \ 24 hours from T cells in the presence of bispecific molecules (5 nM) and C4-2B target cells. Data plotted is within the limit of detection of the assay. B, C. Activation and cytokine release induced by the anti-PSMA x I2C ADAPTIR control molecule. PBMC were stimulated for 20 hrs in the presence of serial dilutions of C4-2B with tandem scFv-scFv (scFv-scFv), the hybrid ADAPTIR molecule or MOR209/ES414 as described before. B. Activation was assessed by measuring the fraction of CD4+ or CD8+ T cells upregulating CD69. C. Cytokine secretion was measured in the culture supernatants. The graphs show levels of IL-2, and IFN-γ; similar trends were observed for TNFα, GM-CSF, IL-4, IL-5 IL-10, IL-13 and IL-17. The figure shows representative results obtained from two independent experiments, each including 2 different human PBMC donors.
sup Figure S7 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S7. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with vincristine sulfate. (see legend SupFigure-S4)
Sup Figure S8 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S8. Time course analysis of pDC activation by CpG- Dbait. Representative experiments of time course analysis of pDC activation by flow cytometry analysis of cell membrane activation markers (A) and interferon release by ELISA assay (B) in presence of doses escalation of CpG-Dbait molecules.
Supplementary Table 1 from Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma
Authors: Lescarbeau Rebecca S. , Lei Liang , Bakken Katrina K. , Sims Peter A. , Sarkaria Jann N. , Canoll Peter , White Forest M.
Published: April 2023

Supplementary Table S1. Phosphorylation Quantification Data and Cell Type-Specific Expression.
Sup Figure S6 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S6. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with irradiations. (see legend SupFigure-S4)
Supplementary Figure 1 from Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma
Authors: Lescarbeau Rebecca S. , Lei Liang , Bakken Katrina K. , Sims Peter A. , Sarkaria Jann N. , Canoll Peter , White Forest M.
Published: April 2023

Supplementary Figure S1. Annotated manually validated MS/MS spectra for phosphopeptides identified in this manuscript.
Sup Figure S4 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S4. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with Etoposide: Cell survival was determined by MTT assay after four days of treatment. Data are presented as the association of AsiDNA on Etoposide efficiency (blue), the effect of Etoposide on AsiDNA efficiency (red), and the isobolograms of this association at the half maximal effective concentration of the two treatments (black). The envelope of additivity calculated from single treatments data is indicated by the dotted black line.
Supplementary Tables S1-S4, Figures S1-S6,Supplementary Methods, and Supplementary Figure Legend from A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer
Authors: Pan Youli , Zheng Mingwu , Zhong Lei , Yang Jiao , Zhou Shu , Qin Ya , Xiang Rong , Chen Yuzong , Yang Sheng-Yong
Published: April 2023

Table S1: Enzymatic activities of SKLB261 against recombinant human protein kinases. Table S2: IC50 values (microM) for inhibition of cell growth after treatment with SKLB261, gemcitabine, erlotinib, dasatinib, or sunitinib for 72 h. Table S3: Pharmacokinetic parameters for SKLB261 in Spragueâˆ’Dawley rats. Table S4: Analysis of statistical significance of animal survival after treatment with SKLB261 or other agents. Figure S1: Growth inhibition of pancreatic tumor cell lines after treatment with SKLB261, dasatinib, gemcitabine, erlotinib, or sunitinib. Figure S2: The effect of SKLB261 treatment on tumor weight and body weight of mice with human pancreatic tumor xenografts. Figure S3: Antitumor efficacy of SKLB261 in PANC-1 tumor xenografts. Figure S4: Effect of SKLB261 on tumor angiogenesis in vivo. Figure S5: The effect of SKLB261 on tumor angiogenesis after treatment for 3 days or 5 days. Figure S6: Anti-metastatic activities of SKLB261 against pancreatic cancer cells in vitro.
Supplementary Figures 1-11 and Supplementary Tables 1-2 from Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model
Authors: Teng Kun-Yu , Han Jianfeng , Zhang Xiaoli , Hsu Shu-Hao , He Shun , Wani Nissar A. , Barajas Juan M. , Snyder Linda A. , Frankel Wendy L. , Caligiuri Michael A. , Jacob Samson T. , Yu Jianhua , Ghoshal Kalpana
Published: April 2023

Supplementary Fig. 1. Mice treated with CCL2 neutralizing antibody (nab) for 4 weeks did not show significant changes in body weight; Supplementary Fig. 2. CCR2 inhibitor therapy reduces chronic liver inflammation in miR-122 knockout (KO) mouse; Supplementary Fig. 3. CCL2 nab therapy did not reduce CD11bhighGr1+ inflammatory myeloid cells in the peripheral blood; Supplementary Fig. 4. Blocking the CCL2-CCR2 axis reduces hepatic macrophages; Supplementary Fig. 5. CCL2 nab does not alter the population of B cell, T cell, and NK cell in liver; Supplementary Fig. 6. CCR2 inhibitor therapy reduces CD11bhighGr1+ inflammatory cells in the KO mouse liver; Supplementary Fig. 7. 12-month-old male KO mice were assigned to vehicle and CCL2 nab treated groups based on serum AFP and body weight; Supplementary Fig. 8. CCL2 immunotherapy reduces tumoral p-STAT3, c-MYC, and p65 levels. Supplementary Fig. 9. CCL2 immunotherapy reduces the number of proliferative cells in the adjacent benign tumors; Supplementary Fig. 10. Blocking CCL2 by neutralizing antibody increases cell apoptosis; Supplementary Fig. 11 CCL2 nab therapy inhibits HCC development in KO mice by modulating tumor microenvironment; Supplementary Table 1. Primers used for RT-qPCR analysis; Supplementary Table 2. Serological analysis of 4 months old KO mice.
Supplementary Figure 6 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

The body weight change of Kasumi-1 xenograft mice during and after indicated treatments.
Supplementary Figure 5 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

The cell cycle analysis of Kasumi-1, KG-1 and K562 cells treated with BPR1J373
Supplementary Table 1 from MicroRNA-720 Regulates E-cadherin–αE-catenin Complex and Promotes Renal Cell Carcinoma
Authors: Bhat Nadeem S. , Colden Melissa , Dar Altaf A. , Saini Sharanjot , Arora Prerna , Shahryari Varahram , Yamamura Soichiro , Tanaka Yuichiro , Kato Taku , Majid Shahana , Dahiya Rajvir
Published: April 2023

Patient characteristics
Supplementary Figure 3 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

BPR1J373 induces apoptosis in Kasumi-1 and KG-1 cells
Supplementary Methods and References from Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression
Authors: Lee Jung-Eun , Kim Chan , Yang Hannah , Park Intae , Oh Nuri , Hua Serenus , Jeong Haneul , An Hyun Joo , Kim Sun Chang , Lee Gyun Min , Koh Gou Young , Kim Ho Min
Published: April 2023

Supplementary Methods and References
Supplementary figure S3 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Authors: Cornet Sébastien , Mathé Doriane , Chettab Kamel , Evesque Anne , Matera Eva-Laure , Trédan Olivier , Dumontet Charles
Published: April 2023

We compared the variations measured for the different leukocyte subpopulations according to treatment. For each subpopulation assessed, pegfilgrastim plus rituximab treatment induced an increase in the number of cells (p<0,05) when compared to rituximab alone). Interestingly the activated monocyte population was multiplied 19-fold and the granulocyte population 18-fold.
Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Authors: Hoda Mir A. , Pirker Christine , Dong Yawen , Schelch Karin , Heffeter Petra , Kryeziu Kushtrim , van Schoonhoven Sushilla , Klikovits Thomas , Laszlo Viktoria , Rozsas Anita , Ozsvar Judit , Klepetko Walter , Döme Balazs , Grusch Michael , Hegedüs Balazs , Berger Walter
Published: April 2023

Supplementary Table S1: Source, background, histology of the tumor and sensitivity towards trabectedin and cisplatin of all mesothelial and mesothelioma cell models used Supplementary Table S2: Cell death-related genes most differently expressed between more and less trabectedin-sensitive mesothelioma cell models
Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Authors: Hoda Mir A. , Pirker Christine , Dong Yawen , Schelch Karin , Heffeter Petra , Kryeziu Kushtrim , van Schoonhoven Sushilla , Klikovits Thomas , Laszlo Viktoria , Rozsas Anita , Ozsvar Judit , Klepetko Walter , Döme Balazs , Grusch Michael , Hegedüs Balazs , Berger Walter
Published: April 2023

Supplementary Figure S1: Sensitivity of pleural mesothelioma cell models to trabectedin and impact of the histological origin Supplementary Figure S2: Impact of trabectedin on the migratory potential of pleural mesothelioma cell models Supplementary Figure S3: Widely synergistic activity of trabectedin and cisplatin in pleural mesothelioma cell models Supplementary Figure S4: Association between bcl-2 expression in mesothelioma cell models and response to trabectedin Supplementary Figure S5: Trabectedin synergizes with the bcl-2 inhibitor obatoclax in pleural mesothelioma cell models independent of cisplatin resistance Supplementary Figure S6: Trabectedin synergizes with the bcl-2 inhibitor ABT-199 in pleural mesothelioma cell models
Supplemental data legends from Mechanism-Based Drug Combinations with the DNA Strand–Breaking Nucleoside Analog CNDAC
Authors: Liu Xiaojun , Jiang Yingjun , Nowak Billie , Hargis Sarah , Plunkett William
Published: April 2023

legends for 6 supplemental figures and 1 supplemental table
Supplementary Figure S1: Combined treatment with OBP-801 and celecoxib reduces FLIP and survivin expression at mRNA level. from A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
Authors: Toriyama Seijiro , Horinaka Mano , Yasuda Shusuke , Taniguchi Tomoyuki , Aono Yuichi , Takamura Toshiya , Morioka Yukako , Miki Tsuneharu , Ukimura Osamu , Sakai Toshiyuki
Published: April 2023

T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. Quantitative real-time RT-PCR of FLIP (A) and survivin (B) mRNA were performed. The internal control was β2MG. Values show fold change in the target gene expression compared with control (DMSO treatment). Data represent the means of triplicates with SD.
Supplementary figure legends from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models
Authors: Jansen Marc H.A. , Lagerweij Tonny , Sewing A. Charlotte P. , Vugts Danielle J. , van Vuurden Dannis G. , Molthoff Carla F.M. , Caretti Viola , Veringa Susanna J.E. , Petersen Naomi , Carcaboso Angel M. , Noske David P. , Vandertop W. Peter , Wesseling Pieter , van Dongen Guus A.M.S. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Supplementary figure legends, supplementary figure 1 and 2
Supplemental Table S1 from The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma
Authors: Olsson P. Olof , Gustafsson Renata , in 't Zandt René , Friman Tomas , Maccarana Marco , Tykesson Emil , Oldberg Åke , Rubin Kristofer , Kalamajski Sebastian
Published: April 2023

Summary of real-time PCR results. Table showing expression levels of selected genes
Supplemental figure 1 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models
Authors: Jansen Marc H.A. , Lagerweij Tonny , Sewing A. Charlotte P. , Vugts Danielle J. , van Vuurden Dannis G. , Molthoff Carla F.M. , Caretti Viola , Veringa Susanna J.E. , Petersen Naomi , Carcaboso Angel M. , Noske David P. , Vandertop W. Peter , Wesseling Pieter , van Dongen Guus A.M.S. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

A heatmap generated using K-means clustering of expression of VEGF-A associated genes; LG-BSG samples (blue) in the disease type histology (upper legends) cluster with normal brain (purple). DIPG (red) clusters with GBM (green). DIPG (green), pHGG/GBM (red).
Supplementary Figure 3 from Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma
Authors: Qin Zhiqiang , Dai Lu , Trillo-Tinoco Jimena , Senkal Can , Wang Wenxue , Reske Tom , Bonstaff Karlie , Del Valle Luis , Rodriguez Paulo , Flemington Erik , Voelkel-Johnson Christina , Smith Charles D. , Ogretmen Besim , Parsons Chris
Published: April 2023

PDF file - 336K, Profiling of bioactive sphingolipids within PEL cells from tumor-bearing mice treated with ABC294640.
Supplementary Figure 2 from Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma
Authors: Qin Zhiqiang , Dai Lu , Trillo-Tinoco Jimena , Senkal Can , Wang Wenxue , Reske Tom , Bonstaff Karlie , Del Valle Luis , Rodriguez Paulo , Flemington Erik , Voelkel-Johnson Christina , Smith Charles D. , Ogretmen Besim , Parsons Chris
Published: April 2023

PDF file - 66K, Confirmation of human PEL tumor expansion in the xenograft model.
Supplementary Table 1. from ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer
Authors: Ruiz de Sabando Ainara , Wang Chao , He Yuanjun , García-Barros Mónica , Kim Julie , Shroyer Kenneth R. , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

The list of antibodies used during this study.
Table S1 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

Genetic features and subtypes of the cell lines used.
Figure S4 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

A, cell growth kinetics of HFF, HFF+hTERT, Saos2, and U2OS cells. B, relative cell growth. C, percent viability of HFF+hTERT and U2OS cells treated with 3 µM 6-thio-dG for 3 days followed by 10 days post-drug removal. D, agarose gel electrophoresis (0.7%) of genomic DNA extracted from HFF+hTERT (lanes 2, 3), U2OS (lanes 4, 5), and HFF (lanes 6, 7) cells treated with DMSO or 3 µM 6-thio-dG treated for 3 days. Lane 1, molecular weight marker, lambda phage DNA/HindIII, is indicated. Gel was run two independent times.
Figure S6 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S6 shows the effects of the combination of streptozotocin with mTOR inhibitors on the number of intrahepatic tumor nodules.
Figure S3 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

A, quantification of genomic damage (γH2AX foci) in TIFs-negative (non-TIF) and TIFs-positive (TIF) HFF+hTERT cells treated or untreated (DMSO) with 3 µM of 6-thio-dG for 3 days. Error bars represent the standard deviation from three independent experiments. P-value is indicated, ***<0.001. B, quantification of γH2AX foci in non-TIF and TIFs-positive HFF+hTERT cells treated with DMSO, imetelstat (IMT; 2 µM), 6-thio-dG (3 µM for 3 days), or in combination as described in figure S2A.
Figure S5 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S5 shows the effects of the combination of streptozotocin with mTOR inhibitors on the size of intrahepatic tumor nodules.
Figure S2 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

A, Telomerase activity in HFF+hTERT cells treated with DMSO, 6-thio-dG (3 µM for 3 days), and imetelstat (IMT; 2 µM). For combination treatment, cells were pre-treated with IMT for 3 days and then with 6-thio-dG for another 3 days. (-) C, (+) C, and IC indicate negative control, positive control, and internal control respectively. Telomerase products are indicated. B-C, effect of telomerase inhibition on cell growth of HFF (B) and HFF+hTERT (C) cells treated with imetelstat (IMT; 2 µM) only, 6-thio-dG (3 µM) only, or 6-thio-dG in combination with imetelstat as described in A. Error bars represent the standard deviation generated from triplicates. P-value, **, P<0.01. D, quantification showing percent cells with TIFs in HFF+hTERT cells treated with imetelstat (IMT; 2 µM) only, 6-thio-dG (3 µM for 3 days), or in combination with imetelstat as described in A. Cells counted for each treatment (n= ~50 cells). Bottom panels show representative images showing TRF2 (green), γH2AX (red), and TIFs (yellow) indicated by white arrows. DAPI (blue) indicates nucleus staining.
Figure S4 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S4 shows how streptozotocin and mTOR inhibitors affect the mTOR pathway and apoptosis in MIN6 cells.
Figure S3 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S3 shows the bliss analyses for combinations of streptozotocin with everolimus, MK-2206, BKM120 or BEZ235 in MIN6 cells.